Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;24(1):57-66.
doi: 10.1007/s10585-007-9057-y. Epub 2007 Mar 15.

Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells

Affiliations

Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells

Anja Elstner et al. Clin Exp Metastasis. 2007.

Abstract

Glioblastoma multiforme are highly invasive brain tumors. Experimental approaches focus on unravelling the mechanisms of invasion, this being a major reason for the poor prognosis of these tumors. Our previous results hinted towards involvement of the iron metabolism in invasion. In this study, we examined the effect of iron depletion on the invasive phenotype of glioblastoma cells. Transwell Matrigel invasion assays were used to monitor iron-dependent invasion of human glioblastoma cell lines U373MG and DBTRG05MG. Intracellular iron concentrations were modulated by applying desferrioxamine (DFO) and ferric ammonium citrate (FAC). We detected enhanced invasion of glioblastoma cells upon DFO-induced iron depletion. Treatment of cells with FAC strongly inhibited invasion. DFO treatment resulted in hypoxia-inducible factor 1 (Hif-1)-mediated induction of urokinase plasminogen activator receptor and matrix metalloproteinase 2. Further, RNA interference-mediated repression of urokinase plasminogen activator receptor inhibited DFO-induced invasion. Our data demonstrate a direct effect of DFO on Hif-1 expression resulting in activation of factors associated with ECM degradation and invasion of glioma cells. These findings caution on utilization of DFO and other iron chelators in the treatment of tumors with invasive potential.

PubMed Disclaimer

References

    1. Mol Cancer Ther. 2005 Sep;4(9):1399-408 - PubMed
    1. Biochem Biophys Res Commun. 2005 Nov 4;336(4):1227-33 - PubMed
    1. Cancer Res. 1996 Aug 15;56(16):3747-51 - PubMed
    1. Anticancer Res. 1995 Sep-Oct;15(5B):2347-50 - PubMed
    1. Oncogene. 2000 Aug 31;19(37):4210-20 - PubMed

MeSH terms

LinkOut - more resources